KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Edwards Lifesciences (EW) FCF Margin (2016 - 2026)

Edwards Lifesciences has reported FCF Margin over the past 17 years, most recently at 22.52% for Q4 2025.

  • For Q4 2025, FCF Margin rose 3532.0% year-over-year to 22.52%; the TTM value through Dec 2025 reached 22.0%, up 1667.0%, while the annual FY2025 figure was 22.0%, 1667.0% up from the prior year.
  • FCF Margin for Q4 2025 was 22.52% at Edwards Lifesciences, down from 33.24% in the prior quarter.
  • Over five years, FCF Margin peaked at 49.76% in Q4 2022 and troughed at 12.79% in Q4 2024.
  • A 5-year average of 18.67% and a median of 20.79% in 2024 define the central range for FCF Margin.
  • Biggest five-year swings in FCF Margin: crashed -4594bps in 2023 and later surged 3532bps in 2025.
  • Year by year, FCF Margin stood at 21.34% in 2021, then skyrocketed by 133bps to 49.76% in 2022, then crashed by -92bps to 3.81% in 2023, then crashed by -435bps to 12.79% in 2024, then skyrocketed by 276bps to 22.52% in 2025.
  • Business Quant data shows FCF Margin for EW at 22.52% in Q4 2025, 33.24% in Q3 2025, and 15.72% in Q2 2025.